{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:05:15Z","timestamp":1776413115685,"version":"3.51.2"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13300-025-01826-4","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T15:42:39Z","timestamp":1764430959000},"page":"165-183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Developing a Comprehensive Approach for Managing Cardiorenal Metabolic Diseases (CRMD) in Saudi Arabia: Thinking beyond Single Disease\u2014Literature Review and Multidisciplinary Consensus Report"],"prefix":"10.1007","volume":"17","author":[{"given":"Abdulrahman","family":"Alshaikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamya","family":"Alzubaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussein","family":"Elbadawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulghani","family":"Alsaeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Almehthel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raed","family":"Aldahash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Alsabaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metib","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussein","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulmohsen","family":"Bakhsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4150-649X","authenticated-orcid":false,"given":"Emad R.","family":"Issak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saud","family":"Alsifri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"issue":"20","key":"1826_CR1","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et\u00a0al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606\u201335.","journal-title":"Circulation"},{"issue":"1","key":"1826_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01937-x","volume":"22","author":"M Marassi","year":"2023","unstructured":"Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023;22(1):195.","journal-title":"Cardiovasc Diabetol"},{"key":"1826_CR3","doi-asserted-by":"crossref","unstructured":"Elheet AA, Alosaimi MA, Alalawi WA, Alasmari AA, Alharbi A, Alhumaidan L, et\u00a0al. Association Between Cardiovascular Disease and Chronic Kidney Disease Prevalence and Characteristics in Saudi Arabia. Cureus [Internet]. 2023 Dec 8 [cited 2025 May 27];15. https:\/\/www.cureus.com\/articles\/199167-association-between-cardiovascular-disease-and-chronic-kidney-disease-prevalence-and-characteristics-in-saudi-arabia","DOI":"10.7759\/cureus.50205"},{"issue":"3","key":"1826_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3755","volume":"40","author":"M Ibrahim","year":"2024","unstructured":"Ibrahim M, Ba-Essa EM, Baker J, Cahn A, Ceriello A, Cosentino F, et\u00a0al. Cardio-renal-metabolic disease in primary care setting. Diabetes Metab Res Rev. 2024;40(3):e3755. https:\/\/doi.org\/10.1002\/dmrr.3755.","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"1826_CR5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.15537\/smj.2024.45.7.20240156","volume":"45","author":"W Mohammedsaeed","year":"2024","unstructured":"Mohammedsaeed W, Alghamdi ZJ. Biomarker for cardiorenal syndrome risk in patients with liver cirrhosis and type 2 diabetes in Saudi Arabia. Saudi Med J. 2024;45(7):675\u201384.","journal-title":"Saudi Med J"},{"issue":"1","key":"1826_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69013-y","volume":"10","author":"A Miller","year":"2020","unstructured":"Miller A, McNamara J, Hummel SL, Konerman MC, Tincopa MA. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. Sci Rep. 2020;10(1):12440.","journal-title":"Sci Rep"},{"issue":"2","key":"1826_CR7","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","volume":"80","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80(2):e76\u20137.","journal-title":"J Hepatol"},{"issue":"2","key":"1826_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biom15020213","volume":"15","author":"N Theodorakis","year":"2025","unstructured":"Theodorakis N, Nikolaou M. From Cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework. Biomolecules. 2025;15(2):213.","journal-title":"Biomolecules"},{"issue":"19","key":"1826_CR9","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14607","volume":"8","author":"SC da Silva Rosa","year":"2020","unstructured":"da Silva Rosa SC, Nayak N, Caymo AM, Gordon JW. Mechanisms of muscle insulin resistance and the cross\u2010talk with liver and adipose tissue. Physiol Rep. 2020;8(19):e14607.","journal-title":"Physiol Rep"},{"issue":"6","key":"1826_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062770","volume":"26","author":"MM Mir","year":"2025","unstructured":"Mir MM, Jeelani M, Alharthi MH, Rizvi SF, Sohail SK, Wani JI, et\u00a0al. Unraveling the mystery of insulin resistance: from principle mechanistic insights and consequences to therapeutic interventions. Int J Mol Sci. 2025;26(6):2770. https:\/\/doi.org\/10.3390\/ijms26062770.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1826_CR11","volume":"27","author":"A Shaito","year":"2022","unstructured":"Shaito A, Aramouni K, Assaf R, Parenti A, Orekhov A, Yazbi AE, et\u00a0al. Oxidative stress-induced endothelial dysfunction in cardiovascular diseases. FBL. 2022;27(3):105.","journal-title":"FBL"},{"issue":"9","key":"1826_CR12","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1007\/s00467-022-05802-z","volume":"38","author":"D Dro\u017cd\u017c","year":"2023","unstructured":"Dro\u017cd\u017c D, Dro\u017cd\u017c M, W\u00f3jcik M. Endothelial dysfunction as a factor leading to arterial hypertension. Pediatr Nephrol. 2023;38(9):2973\u201385.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"1826_CR13","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","volume":"58","author":"B Verg\u00e8s","year":"2015","unstructured":"Verg\u00e8s B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886\u201399.","journal-title":"Diabetologia"},{"issue":"1","key":"1826_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","volume":"34","author":"S Klein","year":"2022","unstructured":"Klein S, Gastaldelli A, Yki-J\u00e4rvinen H, Scherer PE. Cell Metab. 2022;34(1):11\u201320.","journal-title":"Cell Metab"},{"issue":"24","key":"1826_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413238","volume":"25","author":"JAMJL Janssen","year":"2024","unstructured":"Janssen JAMJL. The causal role of ectopic fat deposition in the pathogenesis of metabolic syndrome. Int J Mol Sci. 2024;25(24):13238.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1826_CR16","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031","volume":"71","author":"C Rosso","year":"2019","unstructured":"Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, et\u00a0al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J Hepatol. 2019;71(5):1012\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.031.","journal-title":"J Hepatol"},{"issue":"4","key":"1826_CR17","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","volume":"98","author":"MC Petersen","year":"2018","unstructured":"Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133\u2013223.","journal-title":"Physiol Rev"},{"key":"1826_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00022","volume":"7","author":"A Chait","year":"2020","unstructured":"Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 2020;7:22.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"1826_CR19","volume":"15","author":"F Sugandh","year":"2023","unstructured":"Sugandh F, Chandio M, Raveena F, Kumar L, Karishma F, Khuwaja S, et\u00a0al. Advances in the management of diabetes mellitus: a focus on personalized medicine. Cureus. 2023;15(8):e43697.","journal-title":"Cureus"},{"issue":"8","key":"1826_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082833","volume":"14","author":"V Mutruc","year":"2025","unstructured":"Mutruc V, Bologa C, \u0218orodoc V, Ceasovschih A, Mor\u0103ra\u0219u BC, \u0218orodoc L, et\u00a0al. Cardiovascular\u2013kidney\u2013metabolic syndrome: a new paradigm in clinical medicine or going back to basics? J Clin Med. 2025;14(8):2833. https:\/\/doi.org\/10.3390\/jcm14082833.","journal-title":"J Clin Med"},{"issue":"16","key":"1826_CR21","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et\u00a0al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840\u201378.","journal-title":"Circulation"},{"issue":"7","key":"1826_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071169","volume":"17","author":"V Quagliariello","year":"2025","unstructured":"Quagliariello V, Berretta M, Bisceglia I, Giacobbe I, Iovine M, Barbato M, et\u00a0al. In the era of cardiovascular\u2013kidney\u2013metabolic syndrome in cardio-oncology: from pathogenesis to prevention and therapy. Cancers (Basel). 2025;17(7):1169.","journal-title":"Cancers (Basel)"},{"key":"1826_CR23","unstructured":"Yehuda Handelsman MD. Diabetes, Cardiorenal, and Metabolic Multispecialty Practice Recommendations and Early Intensive Management of Cardio-Renal-Metabolic Disease. 2024 Dec 20 [cited 2025 Jun 2]; https:\/\/www.ajmc.com\/view\/diabetes-cardiorenal-and-metabolic-multispecialty-practice-recommendations-and-early-intensive-management-of-cardio-renal-metabolic-disease"},{"issue":"5","key":"1826_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/1753-0407.13266","volume":"14","author":"A Sonmez","year":"2022","unstructured":"Sonmez A, Sabbour H, Echtay A, Rahmah AM, Alhozali AM, Al Sabaan FS, et\u00a0al. Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: expert recommendations. J Diabetes. 2022;14(5):315\u201333.","journal-title":"J Diabetes"},{"issue":"1","key":"1826_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02347-3","volume":"23","author":"N Zhang","year":"2024","unstructured":"Zhang N, Liu X, Wang L, Zhang Y, Xiang Y, Cai J, et\u00a0al. Lifestyle factors and their relative contributions to longitudinal progression of cardio-renal-metabolic multimorbidity: a prospective cohort study. Cardiovasc Diabetol. 2024;23(1):265.","journal-title":"Cardiovasc Diabetol"},{"key":"1826_CR26","doi-asserted-by":"crossref","unstructured":"Usherwood T. Therapeutic inertia. Australian Prescriber [Internet]. _publication_date_ [cited 2025 Jun 2];47(1). https:\/\/australianprescriber.tg.org.au\/articles\/therapeutic-inertia.html","DOI":"10.18773\/austprescr.2024.001"},{"issue":"26","key":"1826_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196216","volume":"12","author":"W Eskridge","year":"2023","unstructured":"Eskridge W, Cryer DR, Schattenberg JM, Gastaldelli A, Malhi H, Allen AM, et\u00a0al. Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective. J Clin Med. 2023;12(26):6216.","journal-title":"J Clin Med"},{"key":"1826_CR28","unstructured":"Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Jun 3]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/"},{"issue":"1","key":"1826_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/obr.12465","volume":"18","author":"R Burcelin","year":"2017","unstructured":"Burcelin R, Gourdy P. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. Obes Rev. 2017;18(1):86\u201398. https:\/\/doi.org\/10.1111\/obr.12465.","journal-title":"Obes Rev"},{"issue":"12","key":"1826_CR30","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.jdiacomp.2017.08.005","volume":"31","author":"E Gourgari","year":"2017","unstructured":"Gourgari E, Wilhelm EE, Hassanzadeh H, Aroda VR, Shoulson I. A comprehensive review of the FDA-approved labels of diabetes drugs: indications, safety, and emerging cardiovascular safety data. J Diabetes Complications. 2017;31(12):1719\u201327. https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.08.005.","journal-title":"J Diabetes Complications"},{"key":"1826_CR31","doi-asserted-by":"crossref","unstructured":"Khodeer DM. Beyond Glycemic Control: Cardiovascular, Renal, and Hepatic Benefits of GLP-1 Receptor Agonists. Spectrum Science Journal [Internet]. 2024 Nov 1 [cited 2025 Jun 3]; https:\/\/journals.ekb.eg\/article_396448.html","DOI":"10.21608\/sasj.2024.396448"},{"issue":"4","key":"1826_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47040285","volume":"47","author":"M Al Qassab","year":"2025","unstructured":"Al Qassab M, Mneimneh M, Jradi A, Derbas B, Dabboussi D, Khoury Baini J, et\u00a0al. The expanding role of GLP-1 receptor agonists: advancing clinical outcomes in metabolic and mental health. Curr Issues Mol Biol. 2025;47(4):285. https:\/\/doi.org\/10.3390\/cimb47040285.","journal-title":"Curr Issues Mol Biol"},{"key":"1826_CR33","doi-asserted-by":"publisher","first-page":"zxaf053","DOI":"10.1093\/ajhp\/zxaf053","volume":"82","author":"L Salama","year":"2025","unstructured":"Salama L, Sinn L. On the frontlines of cardiovascular-kidney-metabolic syndrome: a review of GLP-1 and dual GLP-1\/GIP receptor agonists in cardiovascular and kidney health. Am J Health Syst Pharm. 2025;82:zxaf053.","journal-title":"Am J Health Syst Pharm"},{"key":"1826_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367. https:\/\/doi.org\/10.1177\/20420188231222367.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"25","key":"1826_CR35","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et\u00a0al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(25):1113\u201324.","journal-title":"N Engl J Med"},{"issue":"2","key":"1826_CR36","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et\u00a0al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(2):896\u2013907.","journal-title":"N Engl J Med"},{"issue":"8","key":"1826_CR37","volume":"16","author":"C Sreenivasan","year":"2024","unstructured":"Sreenivasan C, Parikh A, Francis AJ, Kanthajan T, Pandey M, AlQassab O, et\u00a0al. Evaluating cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus: a systematic review. Cureus. 2024;16(8):e66697.","journal-title":"Cureus"},{"issue":"7","key":"1826_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera FB, Cruz LLA, Magalong JV, Ruyeras JMMJ, Aparece JP, Bantayan NRB, et\u00a0al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024;18(7):100679.","journal-title":"Am J Prev Cardiol"},{"issue":"1","key":"1826_CR39","first-page":"S179","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024. Diabetes Care. 2023;47(1):S179-218.","journal-title":"Diabetes Care"},{"issue":"14","key":"1826_CR40","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et\u00a0al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(14):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"1","key":"1826_CR41","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","volume":"81","author":"VL Chen","year":"2025","unstructured":"Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, et\u00a0al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance. Hepatology. 2025;81(1):312\u201320. https:\/\/doi.org\/10.1097\/HEP.0000000000001112.","journal-title":"Hepatology"},{"issue":"1","key":"1826_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02461-2","volume":"23","author":"KC Chang","year":"2024","unstructured":"Chang KC, Kuo FC, Yang CY, Yang CT, Ou HT, Kuo S. Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case\u2013control study. Cardiovasc Diabetol. 2024;23(1):367.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1826_CR43","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","volume":"105","author":"A Levin","year":"2024","unstructured":"Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et\u00a0al. Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684\u2013701. https:\/\/doi.org\/10.1016\/j.kint.2023.10.016.","journal-title":"Kidney Int"},{"issue":"3","key":"1826_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030399","volume":"18","author":"R Salvador","year":"2025","unstructured":"Salvador R, Moutinho CG, Sousa C, Vinha AF, Carvalho M, Matos C. Semaglutide as a GLP-1 agonist: a breakthrough in obesity treatment. Pharmaceuticals. 2025;18(3):399. https:\/\/doi.org\/10.3390\/ph18030399.","journal-title":"Pharmaceuticals"},{"issue":"6","key":"1826_CR45","doi-asserted-by":"publisher","first-page":"589","DOI":"10.4158\/EP-2018-0444","volume":"25","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, Bellary S, Hramiak I, Seino Y, Silver R, Damgaard LH, et\u00a0al. Greater Combined reductions in Hba1C \u22651.0% and weight \u22655.0% with semaglutide versus comparators in type 2 diabetes. Endocr Pract. 2019;25(6):589\u201397.","journal-title":"Endocr Pract"},{"issue":"5","key":"1826_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.103024","volume":"18","author":"AK Singh","year":"2024","unstructured":"Singh AK, Singh R, Singh A, Misra A. Efficacy and safety of oral semaglutide in type 2 diabetes: a systematic review of real-world evidence. Diabetes Metab Syndr Clin Res Rev. 2024;18(5):103024.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"11","key":"1826_CR47","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et\u00a0al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"1","key":"1826_CR48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/dom.14863","volume":"25","author":"NC Bergmann","year":"2023","unstructured":"Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab. 2023;25(1):18\u201335. https:\/\/doi.org\/10.1111\/dom.14863.","journal-title":"Diabetes Obes Metab"},{"key":"1826_CR49","unstructured":"Wilson, L, Zhao Z, Divino V, Bassan M, Hartaigh BO, Ozer K. Semaglutide is associated with a lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice. Results from the STEER study (semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world). In Madrid, Spain; 2025."},{"issue":"12","key":"1826_CR50","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et\u00a0al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"7","key":"1826_CR51","volume":"16","author":"N Gupta","year":"2024","unstructured":"Gupta N, Uwawah TD, Singh K, Madan H, Kumar S, Midha B, et\u00a0al. Semaglutide in heart failure: a systematic review of outcomes of semaglutide in heart failure patients. Cureus. 2024;16(7):e64668.","journal-title":"Cureus"},{"issue":"2","key":"1826_CR52","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et\u00a0al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"1826_CR53","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","volume":"103","author":"KR Tuttle","year":"2023","unstructured":"Tuttle KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, Lawson J, Mosenzon O, et\u00a0al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int. 2023;103(4):772\u201381. https:\/\/doi.org\/10.1016\/j.kint.2022.12.028.","journal-title":"Kidney Int"},{"issue":"11","key":"1826_CR54","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.2337\/dc25-0472","volume":"48","author":"P Rossing","year":"2025","unstructured":"Rossing P, Bakris G, Perkovic V, Pratley R, Tuttle KR, Mahaffey KW, et\u00a0al. Effects of semaglutide with or without concomitant mineralocorticoid receptor antagonist use in participants with type 2 diabetes and chronic kidney disease: a FLOW trial prespecified secondary analysis. Diabetes Care. 2025;48(11):1878\u201387.","journal-title":"Diabetes Care"},{"issue":"21","key":"1826_CR55","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et\u00a0al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399.","journal-title":"N Engl J Med"},{"issue":"12","key":"1826_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12122689","volume":"12","author":"IKS Boboc","year":"2024","unstructured":"Boboc IKS, Dumitrelea PD, Meca AD, Mititelu-Tartau L, Bogdan M. Exploring the impact of semaglutide on cognitive function and anxiety-related behaviors in a murine model of Alzheimer\u2019s disease. Biomedicines. 2024;12(12):2689.","journal-title":"Biomedicines"},{"issue":"6","key":"1826_CR57","doi-asserted-by":"publisher","first-page":"5929","DOI":"10.3390\/cimb46060354","volume":"46","author":"AD Meca","year":"2024","unstructured":"Meca AD, Boboc IKS, Mititelu-Tartau L, Bogdan M. Unlocking the potential: semaglutide\u2019s impact on Alzheimer\u2019s and Parkinson\u2019s disease in animal models. Curr Issues Mol Biol. 2024;46(6):5929\u201349.","journal-title":"Curr Issues Mol Biol"},{"issue":"12","key":"1826_CR58","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND, et\u00a0al. Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024;20(12):8661\u201372.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1826_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01666-7","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, et\u00a0al. Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimers Res Ther. 2025;17(1):14.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1826_CR60","doi-asserted-by":"publisher","first-page":"2477387","DOI":"10.1080\/16549716.2025.2477387","volume":"18","author":"AM Alshangiti","year":"2025","unstructured":"Alshangiti AM, Aldossary MS, Abou-Hussein AI, Aloufi WJ, El Dalatony MM, Alomary SA. Comorbidities of overweight and obesity associated risk factor in Saudi Arabia: a population-based analysis. Glob Health Action. 2025;18(1):2477387.","journal-title":"Glob Health Action"},{"issue":"6","key":"1826_CR61","volume":"15","author":"YM Alenezi","year":"2023","unstructured":"Alenezi YM, Harris R, Morling J, Card T. Prevalence of non-alcoholic fatty liver disease (NAFLD) in Saudi Arabia: systematic review and meta-analysis. Cureus. 2023;15(6):e40308.","journal-title":"Cureus"},{"issue":"1","key":"1826_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.15537\/smj.2023.44.1.20220402","volume":"44","author":"AM Alguwaihes","year":"2023","unstructured":"Alguwaihes AM, Alhozali A, Yahia MM, Abdel-Nabi T, Hatahet MH, Albalkhi NI, et\u00a0al. The prevalence of cardiovascular disease in adults with type 2 diabetes mellitus in Saudi Arabia - CAPTURE study. Saudi Med J. 2023;44(1):57\u201366.","journal-title":"Saudi Med J"},{"issue":"5","key":"1826_CR63","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4103\/sjg.sjg_62_24","volume":"30","author":"SA Alqahtani","year":"2024","unstructured":"Alqahtani SA, Abaalkhail F, Alghamdi S, Bzeizi K, Al-Hamoudi WK, Paik JM, et\u00a0al. The burden of metabolic dysfunction-associated steatotic liver disease and viral hepatitis in Saudi Arabia. Saudi J Gastroenterol. 2024;30(5):310\u20138.","journal-title":"Saudi J Gastroenterol"},{"issue":"2","key":"1826_CR64","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s13300-023-01516-z","volume":"15","author":"A Alsheikh","year":"2024","unstructured":"Alsheikh A, Alshehri A, Alzahrani S, Jammah AA, Alqahtani F, Alotaibi M, et\u00a0al. Evaluating the clinical effectiveness and safety of semaglutide in individuals with uncontrolled type 2 diabetes. Real-world evidence from Saudi Arabia: the observational, multicenter, 15-month EVOLUTION study. Diabetes Ther. 2024;15(2):473\u201385.","journal-title":"Diabetes Ther"},{"key":"1826_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.deman.2024.100209","volume":"14","author":"A Alsheikh","year":"2024","unstructured":"Alsheikh A, Alshehri A, Alzahrani S, AlJammah A, Alqahtani F, Alotaibi M, et\u00a0al. Oral semaglutide effectiveness and safety in real world practice; the REVOLUTION study. Diabetes Epidemiol Manage. 2024;14:100209.","journal-title":"Diabetes Epidemiol Manage"},{"issue":"6","key":"1826_CR66","doi-asserted-by":"publisher","first-page":"361","DOI":"10.5144\/0256-4947.2024.361","volume":"44","author":"MI Butt","year":"2024","unstructured":"Butt MI, Alkhalifah KM, Riazuddin M, Almuammar SM, Almuammar SM, Alhifthi GA, et\u00a0al. Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia. Ann Saudi Med. 2024;44(6):361\u20138.","journal-title":"Ann Saudi Med"},{"issue":"6","key":"1826_CR67","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131\u201357.","journal-title":"Gastroenterology"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01826-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01826-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01826-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:11Z","timestamp":1771268591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01826-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1826"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01826-4","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Abdulrahman Alshaikh, Ali Alshehri, Lamya Alzubaidi, Hussein Elbadawi, Abdulghani Alsaeed, Mohammed Almehthel, Raed Aldahash, Fahad Alsabaan, Metib Alotaibi, Khalid Alghamdi, Hussein Alamri, Abdulmohsen Bakhsh, Emad R. Issak, and Saud Alsifri have nothing to disclose. Marc Evans is a co-editor-in-chief of the journal\n                      Diabetes Therapy\n                      . Marc Evans was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}